Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists
18 Years
48 Years
Female
Prolactinoma, Insulin Resistance, Hyperlipidemia
Trial Information
Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists
A cross-sectional study was performed in non-obese premenopausal women with prolactinoma
treated with dopamine agonists evaluated regarding glucose, insulin, Homeostasis Model
Assessment (HOMA), lipid profile, C reactive protein (CRP), body mass index (BMI), waist
circumference, prolactin, estradiol, testosterone, and sex hormone binding globulin (SHBG).
They were compared with control women of similar age and BMI distribution.
Inclusion Criteria:
- Prolactinoma
- Female gender
- Premenopausal
Exclusion Criteria:
- Obesity (BMI ≥ 30 kg/m²)
- Diabetes mellitus
- Hypertension
- GH deficiency
- Hypothyroidism
- Primary hypogonadism
- Adrenal insufficiency
- Pituitary surgery
Type of Study:
Observational
Study Design:
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional, Time Perspective: Prospective
Principal Investigator
Erika CO Naliato, MSc
Investigator Role:
Principal Investigator
Investigator Affiliation:
Federal University of Rio de Janeiro - Brazil
Authority:
Brazil: National Committee of Ethics in Research
Study ID:
178/04
NCT ID:
NCT00481299
Start Date:
October 2004
Completion Date:
September 2006
Related Keywords:
- Prolactinoma
- Insulin Resistance
- Hyperlipidemia
- Insulin
- glucose
- lipids
- prolactinoma
- hyperprolactinemia
- Hyperlipidemias
- Insulin Resistance
- Prolactinoma
Name | Location |
|---|
